- Home
- NRIX vs IMAX Comparison
NRIX vs IMAX Comparison
Compare NRIX & IMAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIX | IMAX |
|---|---|---|
| Founded | 2009 | 1967 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.4B |
| IPO Year | 2020 | 1997 |
Fundamental Metrics
Financial Performance| Metric | NRIX | IMAX |
|---|---|---|
| Price | $26.16 | $50.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 10 |
| Target Price | $30.50 | ★ $44.50 |
| AVG Volume (30 Days) | 976.1K | ★ 1.3M |
| Earning Date | 04-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.25 |
| EPS | N/A | ★ 0.35 |
| Revenue | $76,987,000.00 | ★ $410,212,000.00 |
| Revenue This Year | N/A | $9.79 |
| Revenue Next Year | $48.05 | $7.51 |
| P/E Ratio | ★ N/A | $148.40 |
| Revenue Growth | ★ 99.31 | 16.47 |
| 52 Week Low | $8.20 | $28.42 |
| 52 Week High | $28.23 | $55.57 |
Technical Indicators
Market Signals| Indicator | NRIX | IMAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.11 | 54.37 |
| Support Level | $14.63 | $34.27 |
| Resistance Level | $28.23 | N/A |
| Average True Range (ATR) | 0.94 | 1.96 |
| MACD | -0.19 | -0.44 |
| Stochastic Oscillator | 34.11 | 30.75 |
Price Performance
Historical ComparisonAbout NRIX Nurix Therapeutics Inc.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
About IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.